v3.26.1
Fair Value of Financial Instruments - Schedule of Amortized Cost and Fair Value of Performing and Non-Accrual Investments (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Amortized cost $ 890,527 [1],[2],[3] $ 936,824 [4],[5],[6],[7]
Fair Value 887,607 937,725
Performing [Member]    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Amortized cost 889,907 936,204
Fair Value 887,306 937,047
Non Accrual [Member]    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Amortized cost 620 620
Fair Value $ 301 $ 678
[1] All investments domiciled in the United States unless otherwise noted.
[2] The Fund updated certain descriptions of its portfolio companies presented in the consolidated financial statements as of March 31, 2026 to align with the legal issuer name, where applicable. These updates had no impact on the Consolidated Statements of Assets and Liabilities as of March 31, 2026.
[3] Unless otherwise noted, the fair value of investments with respect to securities for which market quotations are not readily available are valued using significant unobservable inputs (See Note 3—Fair Value of Financial Instruments).
[4] All investments domiciled in the United States unless otherwise noted.
[5] The Fund updated certain descriptions of its portfolio companies presented in the consolidated financial statements as of December 31, 2025 to align with the legal issuer name, where applicable. These updates had no impact on the Consolidated Statements of Assets and Liabilities as of December 31, 2025.
[6] This security is restricted and not available for resale.
[7] Unless otherwise noted, the fair value of investments with respect to securities for which market quotations are not readily available are valued using significant unobservable inputs (See Note 3—Fair Value of Financial Instruments).